Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies

OBJECTIVE: To evaluate the magnitude of response to secukinumab treatment over 3 years in patients with ankylosing spondylitis (AS) grouped by baseline C-reactive protein (CRP) levels in a pooled study of two pivotal phase III studies: MEASURE 1 (NCT01358175) and MEASURE 2 (NCT01649375). METHODS: Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Braun, Jürgen, Deodhar, Atul, Landewé, Robert, Baraliakos, Xenofon, Miceli-Richard, Corinne, Sieper, Joachim, Quebe-Fehling, Erhard, Martin, Ruvie, Porter, Brian, Gandhi, Kunal K, van der Heijde, Désirée
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269637/
https://www.ncbi.nlm.nih.gov/pubmed/30564451
http://dx.doi.org/10.1136/rmdopen-2018-000749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269637/
https://www.ncbi.nlm.nih.gov/pubmed/30564451
http://dx.doi.org/10.1136/rmdopen-2018-000749

Ejemplares similares